Source:http://linkedlifedata.com/resource/pubmed/id/12874732
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-7-22
|
pubmed:abstractText |
The objective of this study was to analyze if repetitive administration of antenatal steroids (ANS) had an adverse impact on neonatal outcome at hospital discharge in premature infants. We used a retrospective analysis of 306 infants of gestational age (GA) < or = 34 weeks born between January 1997 and June 1999. A detailed review of maternal and neonatal charts was done. Seventy-one percent (216/306) received ANS. While there was no difference in birth weight (1.37 +/- 0.04 versus 1.49 +/- 0.06 kg; p = 0.09), infants receiving ANS were of lesser GA (29.5 +/- 0.2 versus 30.5 +/- 0.4 weeks; p = 0.02). More babies who received ANS had clinical evidence of gastroesophageal reflux (GER) [59/216 (27%) versus 11/90 (12%); p = 0.007]. After correcting for GA, infants receiving ANS were less likely to need surfactant (p = 0.03) and more likely to be diagnosed with clinical GER (p = 0.02). Ninety (29%) infants received no ANS, 47 (15%) received a suboptimal course, 112 (37%) infants received 1 course of ANS, and 57 (19%) infants received > or = 2 courses. There was a significant increase in the incidence of GER with increasing courses of ANS: 0 course 11/90 (12%), suboptimal 12/47 (26%), 1 course 28/112 (25%), 2 or more courses 18/57 (32%); p = 0.006, linear trend. The increased incidence of GER (p = 0.01) still held true among infants who had GER confirmed by a pH-probe study. Use of ANS is associated with a significantly decreased need for surfactant; however, there is an increased incidence of GER.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0735-1631
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
205-13
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12874732-Anti-Inflammatory Agents,
pubmed-meshheading:12874732-Betamethasone,
pubmed-meshheading:12874732-Dexamethasone,
pubmed-meshheading:12874732-Female,
pubmed-meshheading:12874732-Gastroesophageal Reflux,
pubmed-meshheading:12874732-Humans,
pubmed-meshheading:12874732-Infant, Newborn,
pubmed-meshheading:12874732-Infant, Premature,
pubmed-meshheading:12874732-Infant, Premature, Diseases,
pubmed-meshheading:12874732-Logistic Models,
pubmed-meshheading:12874732-Male,
pubmed-meshheading:12874732-Maternal-Fetal Exchange,
pubmed-meshheading:12874732-Pregnancy,
pubmed-meshheading:12874732-Retrospective Studies
|
pubmed:year |
2003
|
pubmed:articleTitle |
Antenatal steroid use is associated with increased gastroesophageal reflux in neonates.
|
pubmed:affiliation |
Department of Pediatrics, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA.
|
pubmed:publicationType |
Journal Article
|